ICER plans to assess the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals, Inc.) and belimumab (BENLYSTA®, GlaxoSmithKline) for the treatment of lupus nephritis. Voclosporin is seeking an initial approval for the treatment of lupus nephritis, and belimumab is seeking a label expansion for the treatment of lupus nephritis; both are expecting FDA decisions in early 2021.
Date of review: March 2021
For questions, please contact Catherine Koola, Program Manager, at email@example.com.
Virtual – details will be available closer to the meeting date
The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for lupus nephritis.